Health Care/Hospital

Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule

CHENGDU, China, July 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that onJuly 10, 2024, NASDAQ notified the Company that it has determined that for the...

2024-07-12 20:30 982

Senhwa Biosciences Clinical Data Abstract of Pidnarulex Accepted for Presentation at 2024 ESMO Congress

TAIPEI and SAN DIEGO, July 12, 2024 /PRNewswire/ -- Senhwa Biosciences' new drug Pidnarulex (CX-5461) has demonstrated efficacy in treating various solid tumors with BRCA2 or PALB2 gene defects. The abstract of this clinical trial has been selected for presentation at the 2024 European Society fo...

2024-07-12 19:00 1241

Smartee Denti-Technology Debuts Themed Airplane with Spring Airlines

SHANGHAI, July 12, 2024 /PRNewswire/ -- Smartee Denti-Technology, in partnership with Spring Airlines, unveiled its inaugural themed airplane at Shanghai Hongqiao International Airport. The event was part of Smartee's 20th-anniversary celebrations.

2024-07-12 15:26 888

CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE

BEIJING, July 11, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it plans to change the ratio of its American d...

2024-07-12 04:00 1592

Medit Appoints Han Ryu as CEO, Focusing on Customer-Centric Innovation

SEOUL, South Korea, July 11, 2024 /PRNewswire/ -- Medit, a global leader in dental 3D scanners and digital dentistry solutions, has appointedHan Ryu as its new CEO. Ryu brings with him over three decades of senior management experience in global medical device and healthcare companies, including ...

2024-07-11 21:00 1645

First Patient Dosed in Phase I Clinical Trial of YOLT-201

SHANGHAI, July 11, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, announced today the successful enrollment of the first patient in the Phase I clinical trial of YOLT-201, its independently developed in vivo g...

2024-07-11 20:11 1222

Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC

SHANGHAI, July 11, 2024 /PRNewswire/ -- Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement. BioGeometry is a digital biology pioneer company that specializes in AI-driven protein design and R&D platform. Sanyou Bio is a world-leading high-tech...

2024-07-11 20:00 1228

Patent rights jointly owned by the National Cancer Center and the University of Pennsylvania, licensed to ARC Therapies, Inc.

Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL) TOKYO, July 11, 2024 /PRNewswire/ -- The National Cancer Center (Tokyo, Japan ) and TheUniversity of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a chimeric anti...

2024-07-11 14:21 1248

ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'

* IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. * Niclosamide-based metabolic anticancer drug aims to block signaling pathways that allow cancer cells to evade anticancer effects, potentially solving the issue ...

2024-07-11 14:07 1200

Official Swiss delegation experiences new frontiers in art tech at HKBU

HONG KONG, July 11, 2024 /PRNewswire/ -- A senior Swiss delegation led by Mr Guy Parmelin, Swiss Federal Councillor and Head of the Federal Department of Economic Affairs, Education and Research, visited Hong KongBaptist University (HKBU) on 5 July. The delegation was able to partake in the premi...

2024-07-11 13:34 1041

Kangsters Unveils Revolutionary Treadmills at Rollettes Experience 2024: Celebrating Innovation and Empowerment

LOS ANGELES, July 10, 2024 /PRNewswire/ -- Kangsters, the pioneering South Korean adaptive tech startup, proudly announces its participation in the Rollettes Experience 2024. This renowned event, now celebrating its 11th anniversary, will be held fromJuly 11-14 at the Sheraton Hotel in Los Angele...

2024-07-11 00:00 1143

Snorles GenioFlex: The Innovative Daytime Solution for Snoring Management Now Launched on Indiegogo

HONG KONG, July 10, 2024 /PRNewswire/ -- Snorles, a leading innovator in sleep technology, is excited to announce the launch of its latest product, GenioFlex. Snorles created to address snoring issues and promote overall health and well-being, GenioFlex offers a fresh approach to managing snoring...

2024-07-10 20:02 1274

WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year

SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year t...

2024-07-10 13:30 1744

KOSÉ, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells

Demonstration testing of "my own" beauty products PALO ALTO, Calif., July 9, 2024 /PRNewswire/ -- KOSÉ Corporation (Headquarters: Chuo-ku,Tokyo; President: Kazutoshi Kobayashi), I Peace, Inc. (Headquarters:Palo Alto, California, USA; Founder & CEO: Koji Tanabe), and Reju, Inc. (Headquarters: Min...

2024-07-09 23:00 1589

Bestqool Pro Series Redefines the Standard of Red Light Therapy Devices: Cutting-Edge Technology Undergone the Third-party Laboratory Diagnostic Testing

NEW YORK, July 9, 2024 /PRNewswire/ -- Bestqool, as one of the industry's top makers of innovative red light therapy devices for over six years, in recent months proactively sent their Pro Series devices to LightLab International Allentown LLC, a reputable third-party laboratory in the US. Bestqo...

2024-07-09 21:00 1294

Goodix Launches Its Latest Automotive-Grade Bluetooth LE SoC and CGM Solutions at electronica China 2024

SHENZHEN, China, July 8, 2024 /PRNewswire/ -- Goodix Technology today unveiled its Continuous Glucose Monitoring (CGM) solutions and automotive-grade Bluetooth LE SoC at the electronicaChina 2024. Demonstrating a dedication to innovation in sensing and wireless technology, Goodix showcased its la...

2024-07-08 22:00 1861

Porton J-STAR and Enabling Technologies Consortium Collaboration on Co-processing Platform Technology Development

CHONGQING, China, July 8, 2024 /PRNewswire/ -- Porton J-STAR today announced that Enabling Technologies Consortium (ETC) has awarded a two-year contract to J-STAR to collaborate on "Co-processing Platform Technology." The primary goal of co-p...

2024-07-08 22:00 1270

Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®

* Tergase® poised to capture a fair share of the global hyaluronidase market. DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- Alteogen Inc.  (KOSDAQ:196170) announced that the Ministry of Food and Drug Safety (MFDS) of Korea approved its New Drug Application (NDA...

2024-07-08 21:00 1737

DP Technology Announces Nomination of Development Candidate, a CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer's Disease

BEIJING, July 8, 2024 /PRNewswire/ -- DP Technology, an "AI for Science" paradigm-driven company, today announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-PLA2, as a preclinical candidate for the treatment of Alzheimer's disease (AD). AD is the most frequent ...

2024-07-08 17:23 1184

DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Lp-PLA2 Inhibitor for DR and DME

* The nomination of novel Lp-PLA2 inhibitor DPT0415 for the treatment of DR & DME. * DPT0415 is a highly potent, selective and safe Lp-PLA2 inhibitor with sufficient target engagement at a dose of 0.3 mpk and robust efficacy in the STZ-induced rat DR model. * This project further validates ...

2024-07-08 17:00 1122
12345 ... 261